Topic

Articles

Successful oncolytic virus immunotherapy clinical development requires unique features that focus on viral biology and host immune response.

Oncolytic Virus Immunotherapy: A Brief Overview and Considerations for Clinical Trial Planning 

Steps that investigators and sponsors can take to streamline trials and accelerate the time to market for lifesaving therapies.

Streamlining the Complex Respiratory Clinical Trial Infrastructure

Five therapeutic areas that are apt for an all-virtual approach, and that can serve as an entry point for sponsors who are hesitant yet interested in exploring the growing DCT model.

Decentralized Clinical Trials: What Therapeutic Areas are Ripe for All-Virtual?

Vanessa Tassell, Vice President of Clinical Operations at Mirati Therapeutics, will discuss how some enterprises are navigating trials by incorporating strategies to expand clinical trial access to patients who need it.

New Operational Methods Emerge in Cancer Clinical Trials

Clinical Vice President, Internal Medicine, Signant Health

Poor representation of dark skin tones in textbooks emphasizes need for change.

Properly Training Physicians in Dermatology Trials

The diversified sources of the somatic cells call for additional oversight to prevent the introduction, transmission, and spread of communicable disease.

Somatic Cell Therapy—Navigating the Regulatory Landscape 

RWE can augment, extend, or enrich the findings from clinical trials to provide valuable evidence to support the development programs for product approvals. 

Augmenting Single Arm Oncology and Rare Disease Trials with Real World Evidence

Do Oncology Clinical Trial Participants Cost More for Payers?

Survey data shows individuals are not informed on how COVID-19 could affect their conditions.

Rare Disease Patients Overlooked During COVID

Developing new pathways to overcome study-related challenges is key to realizing the promise of the latest gene therapies.